Assessing novel biomarkers in pacemaker induced cardiomyopthy

Abstract not completed yet but background information below.

PICM is a significant and under-recognised complication in patients requiring long-term pacing therapy. It is characterised by a deterioration in cardiac function due to mechanical and electrical alterations caused by pacing the right ventricle, through muscle, which can then lead to disease of the heart muscle (Khurshid et al., 2014). The aim of this project is to identify and quantify novel biomarkers that are associated with PICM. This research will involve a detailed examination and comparison of novel biomarker levels with echocardiography findings and patient history. By identifying novel biomarkers, it will allow us to understand further the molecular and genetic factors driving the condition and highlighting potential therapy targets. This ultimately will contribute to more effective diagnosis, management and treatment of PICM.

Furthermore, identifying novel biomarkers for the detection of PICM could have a profound impact on NHS costs and wait times by enabling earlier and more accurate diagnosis of this condition. Early detection through reliable biomarkers would allow for timely therapeutic interventions, potentially preventing the progression of PICM to more severe heart failure. This proactive approach would reduce the need for extensive and costly treatments, hospitalisation, and prolonged care associated with advanced cardiomyopathy. Furthermore, by streamlining the diagnostic process, healthcare providers could allocate resources more efficiently, thereby shortening wait times for other patients. Overall, the identification of these biomarkers could contribute to a more efficient, cost-effective healthcare system, enhancing patient outcomes and reducing the strain on NHS resources.

Outputs

Not published yet